Drugs / [177Lu]Ludotadipep
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04509557 | Oct 2020 → Jun 2022 | prostate carcinoma | FutureChem | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05579184 | Oct 2022 → Dec 2024 | castration-resistant prostate carcinoma | FutureChem | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Ludotadipep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04509557 ↗ |
| Route | Intravenous | “slowly i.v. inject over 10 minutes” NCT04509557 ↗ |